# Oculis Holding AG share price today (Oculis Holding AG, OCS)

> Oculis Holding AG's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. OCS · Healthcare · Biotechnology · data as of 4 November 2026. Page: https://www.sectoralpha.in/us/stocks/ocs

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $7.28 (−62.1% in a year)
- Revenue (Jun 2026): $310 K
- Profit (Jun 2026), incl. one-off: −$10.0 M (one-off item, see below)
- ROE: −51%, FY25

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Oculis Holding AG share price today? Oculis Holding AG's share price was $7.28 at the close on 4 November 2026. That is 60.8% below its average price over the last 200 trading days. In the last 52 weeks it traded between $7 and $33, and at that close it was at the low of that range. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 9 weeks running. Over the last 1 year the share price moved −60% while the S&P 500 moved +18%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 4 September 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Oculis Holding AG pay? Oculis Holding AG pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Oculis Holding AG on? Oculis Holding AG is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Oculis Holding AG profitable? Oculis Holding AG posted a net loss of $10.0 M in the Jun 2026 quarter. That quarter includes a one-off gain bigger than its revenue, so the comparison with last year does not reflect normal business. The full FY25 year was a loss of $99.0 M. That loss is 3,216.1% of the quarter's revenue. The same quarter a year earlier lost $25.4 M. 12 of the last 12 reported quarters were loss-making. Read this profit with care: at −$10.0 M it is bigger than the quarter's whole revenue of $310 K. No business earns more than it takes in from sales, so this is a one-off item (for example a debt settlement, a tax write-back or an asset sale), not money the business earned. The underlying business is running at a −7,602.6% operating margin. The jump on last year, and any P/E built on this profit, come from the one-off, not from a real turn in earnings. ## How much revenue does Oculis Holding AG make, and is it growing? Oculis Holding AG reported $310 K of revenue in the Jun 2026 quarter, +18.8% on the same quarter a year earlier. Over 4 years it has grown 5.7% a year on average. The last full year, FY25, came in at $1.2 M. The last four reported quarters add to $1.2 M. FY25 revenue was $1.2 M, +74.8% on the year before. Recent pace: the last four quarters grew +3,401.1% on average, against 5.7% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +53.3%, against +16.0% a year over the last 8 quarters (accelerating). ## How much of every $100 of sales does Oculis Holding AG keep? Oculis Holding AG has almost no sales yet: FY25 revenue was $1.2 M. On sales that small an operating margin is not a useful reading, so this section is left out until sales grow. ## Is Oculis Holding AG's profit turning into cash? Oculis Holding AG's cash-flow history is too short to judge how much of its profit turns into cash. In FY25 its operations used $66.3 M of cash, against −$99.0 M of profit. After $301 K of spending on assets, free cash was −$66.6 M: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Oculis Holding AG's cash go? Oculis Holding AG does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $579 K on assets over the last 3 years. Averaged over those years that is 16.1% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $579 K over the last 3 years. In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it. ## What is Oculis Holding AG's P/E ratio, and how does it compare with its own history? Oculis Holding AG has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values Oculis Holding AG at 374.8× its FY25 revenue of $1.2 M. The P/E comes back here once profit turns positive. ## Is the Oculis Holding AG business getting better or worse? Oculis Holding AG's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. The latest quarter’s profit includes a one-off item bigger than the normal business, so the profit line is shown but does not count in this reading. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Oculis Holding AG earn on its capital? Oculis Holding AG earned a ROE of −51% in FY25. That is up from a low of −117% in FY24. Its return on capital used (ROIC) is left out: on sales this small it reads −33%, a number that says nothing useful about the business. ## Does Oculis Holding AG have too much debt? Oculis Holding AG has total debt of $2.5 M against shareholder equity of $219 M as of Jun 2026, so its debt is 0.01× its equity, which is very little. Year by year, that ratio went from −1.87 in FY21 to 0.01 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the Oculis Holding AG shareholding pattern? 3.4% of Oculis Holding AG's tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 5.6 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Oculis Holding AG from balance-sheet trouble? For Oculis Holding AG, the Z-score is 16.53. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 16.53 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does Oculis Holding AG rank in its industry? There is no score against its industry: Oculis Holding AG is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Oculis Holding AG compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Oculis Holding AG in size? Oculis Holding AG is the 149th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: Gyre Therapeutics, Inc., MiMedx Group, Inc. and Phathom Pharmaceuticals, Inc. Just below it: CorMedix Inc., Prothena Corporation plc and Prelude Therapeutics Incorporated. ### Biotechnology companies close in size

1. [Gyre Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/gyre) $471 million
2. [MiMedx Group, Inc.](https://www.sectoralpha.in/us/stocks/mdxg) $467 million
3. [Phathom Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/phat) $451 million
4. Oculis Holding AG $449 million
5. [CorMedix Inc.](https://www.sectoralpha.in/us/stocks/crmd) $441 million
6. [Prothena Corporation plc](https://www.sectoralpha.in/us/stocks/prta) $431 million
7. [Prelude Therapeutics Incorporated](https://www.sectoralpha.in/us/stocks/prld) $420 million

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [El Pollo Loco Holdings, Inc.](https://www.sectoralpha.in/us/stocks/loco) $473 million · Restaurants
2. [Cerus Corporation](https://www.sectoralpha.in/us/stocks/cers) $472 million · Medical Devices
3. Oculis Holding AG $471 million
4. [Gyre Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/gyre) $471 million · Biotechnology
5. [Ovid Therapeutics Inc.](https://www.sectoralpha.in/us/stocks/ovid) $469 million · Biotechnology

## What else do people ask about Oculis Holding AG? ### What were Oculis Holding AG's latest quarterly results? Oculis Holding AG reported revenue of $310 K and a net loss of $10.0 M for the Jun 2026 quarter. Earnings per share were −$0.16. The operating margin was −7,602.6%, 354.5 percentage points higher than a year earlier (as of 4 November 2026). ### What is Oculis Holding AG's market cap? Oculis Holding AG's market capitalisation is $449 M at a stock price of $7.28. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### How is Oculis Holding AG performing? Oculis Holding AG's latest readings are below. Over the past 13 weeks it has done worse than the S&P 500, for 9 weeks running. This describes what the data did, not a rating (as of 4 November 2026). ### Will Oculis Holding AG's stock price go up? This page does not forecast Oculis Holding AG's stock price. What it shows instead: the stock price is $7.28. Nobody can reliably say which way a price will move, and this site does not try (as of 4 November 2026). ### What could break the Oculis Holding AG story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is Oculis Holding AG a stock worth studying right now? What the numbers show: Oculis Holding AG's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). This is research, not advice. We’re not SEBI-registered.